We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
12 own
2 watching
Current Price
$0
$-0.02
(-2.28%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
200.21M
52-Week High
4.01
52-Week Low
0.4053
Average Volume
0.08M
Dividend Yield
--
P/E Ratio
--
Market Capitalization200.21M
52-Week High4.01
52-Week Low0.4053
Average Volume0.08M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
20days ago
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (Alaunos or the Company) (Nasdaq: TCRT), today announced that it will report financial results for the third quarter ended September 30, 2022 on Monday, November 14, 2022, before the open of U.S. markets. Following the ...
Globe Newswire
21days ago
Data supports high-throughput screening process to identify neoantigen-reactive TCRsExclusive ownership of discovered KRAS mutation-reactive TCRshunTR enables expansion of the Companys hotspot mutation targeted TCR library HOUSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (...
PR Newswire
2 months ago
Thinking about buying stock in Frontier Communications, Edgio, Alaunos Therapeutics, Heartbeam, or Blue Apron? Thinking about buying stock in Frontier Communications, Edgio, Alaunos Therapeutics, Heartbeam, or Blue Apron? PR Newswire NEW YORK, Sept. 28, 2022 NEW YORK, Sept. 28, 2022 /PRNewswire...
PR Newswire
2 months ago
Thinking about buying stock in Rubius Therapeutics, NextPlat, Seres Therapeutics, Cassava Sciences, or Alaunos Therapeutics? Thinking about buying stock in Rubius Therapeutics, NextPlat, Seres Therapeutics, Cassava Sciences, or Alaunos Therapeutics? PR Newswire NEW YORK, Sept. 23, 2022 NEW YORK...
PR Newswire
2 months ago
Thinking about buying stock in FREYR Battery, Palantir Technologies, Carnival Corp, Novavax, or Alaunos Therapeutics? Thinking about buying stock in FREYR Battery, Palantir Technologies, Carnival Corp, Novavax, or Alaunos Therapeutics? PR Newswire NEW YORK, Sept. 22, 2022 NEW YORK, Sept. 22, 2022...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0
$-0.02
(-2.28%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00